➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Colorcon
Medtronic
Mallinckrodt

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tegobuvir

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tegobuvir?

Tegobuvir is an investigational drug.

There have been 5 clinical trials for Tegobuvir. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis A. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and four hundred and four international patents.

Recent Clinical Trials for Tegobuvir
TitleSponsorPhase
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionGilead SciencesPhase 2
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionGilead SciencesPhase 2
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionGilead SciencesPhase 2

See all Tegobuvir clinical trials

Clinical Trial Summary for Tegobuvir

Top disease conditions for Tegobuvir
Top clinical trial sponsors for Tegobuvir

See all Tegobuvir clinical trials

US Patents for Tegobuvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegobuvir   Start Trial Method for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Tegobuvir   Start Trial Methods for treating HCV Gilead Pharmasset LLC (Foster City, CA)   Start Trial
Tegobuvir   Start Trial Pyridazine compound and use thereof Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AU)   Start Trial
Tegobuvir   Start Trial Pyridazine compound and use thereof Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegobuvir

Drugname Country Document Number Estimated Expiration Related US Patent
Tegobuvir Australia AU2014239563 2033-03-14   Start Trial
Tegobuvir Australia AU2015240754 2033-03-14   Start Trial
Tegobuvir Australia AU2016202823 2033-03-14   Start Trial
Tegobuvir Australia AU2016291154 2033-03-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.